Published in Biol Blood Marrow Transplant on February 06, 2010
Quantitative salivary proteomic differences in oral chronic graft-versus-host disease. J Clin Immunol (2012) 0.89
Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis (2012) 0.87
Proteomic analysis of saliva from patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant (2014) 0.84
Oral complications in hematopoietic stem cell recipients: the role of inflammation. Mediators Inflamm (2014) 0.84
Malnutrition in patients with chronic GVHD. Bone Marrow Transplant (2014) 0.84
Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures. Bone Marrow Transplant (2013) 0.79
Oral cGVHD screening tests in the diagnosis of systemic chronic graft-versus-host disease. Clin Oral Investig (2011) 0.79
Biology of chronic graft-vs-host disease: Immune mechanisms and progress in biomarker discovery. World J Transplant (2016) 0.75
Oral disease profiles in chronic graft versus host disease. J Dent Res (2015) 0.75
Assessing the relationship between oral chronic graft-versus-host disease and global measures of quality of life. Oral Oncol (2015) 0.75
Surveillance for dental caries, dental sealants, tooth retention, edentulism, and enamel fluorosis--United States, 1988-1994 and 1999-2002. MMWR Surveill Summ (2005) 5.40
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood (2013) 3.45
GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med (2006) 3.38
The cancer survivor's prescription for living. Am J Nurs (2007) 3.37
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood (2011) 3.02
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood (2011) 2.66
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain (2010) 2.41
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood (2011) 2.26
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (2006) 2.24
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood (2012) 2.19
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA (2009) 1.88
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant (2006) 1.86
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood (2011) 1.83
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Candidate gene studies of human pain mechanisms: methods for optimizing choice of polymorphisms and sample size. Anesthesiology (2004) 1.78
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant (2010) 1.69
Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg (2012) 1.59
Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant (2009) 1.57
The 2009-2013 research agenda for oncology nursing. Oncol Nurs Forum (2009) 1.57
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant (2011) 1.54
Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology (2011) 1.50
p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB. Oncogene (2003) 1.45
Chronic graft versus host disease. Curr Opin Hematol (2006) 1.38
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant (2010) 1.33
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood (2003) 1.29
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood (2003) 1.25
The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT). Support Care Cancer (2008) 1.25
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood (2004) 1.23
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res (2013) 1.21
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer (2013) 1.21
Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood (2009) 1.20
Transplantation's greatest challenges: advances in chronic graft-versus-host disease. Biol Blood Marrow Transplant (2007) 1.18
National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant (2013) 1.18
Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant (2010) 1.15
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol (2004) 1.15
Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant (2012) 1.10
Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea (2012) 1.10
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant (2011) 1.09
Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Transl Behav Med (2011) 1.07
Selective screening of secretory vesicle-associated proteins for autoantigens in type 1 diabetes: VAMP2 and NPY are new minor autoantigens. Clin Immunol (2008) 1.06
Electronic toxicity monitoring and patient-reported outcomes. Cancer J (2011) 1.06
Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood (2011) 1.05
Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation. Biol Blood Marrow Transplant (2010) 1.05
Cancer-related fatigue and its impact on functioning. Cancer (2013) 1.05
Implementing evidence-based practice: effectiveness of a structured multifaceted mentorship programme. J Adv Nurs (2010) 1.05
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp Hematol (2007) 1.04
Assessment of joint and fascia manifestations in chronic graft-versus-host disease. Arthritis Rheumatol (2014) 1.04
Histopathological and lymphangiogenic parameters in relation to lymph node metastasis in early stage oral squamous cell carcinoma. J Oral Maxillofac Surg (2007) 1.03
Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Proc Natl Acad Sci U S A (2003) 1.02
Modifying cancer-related fatigue by optimizing sleep quality. J Natl Compr Canc Netw (2008) 1.00
Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant (2012) 1.00
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood (2013) 0.99
A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Mol Pain (2006) 0.99
Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). Clin Proteomics (2012) 0.98
Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol. Health Qual Life Outcomes (2011) 0.98
The formation of inflammatory demyelinated lesions in cerebral white matter. Ann Neurol (2014) 0.98
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 0.96
Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses. Arch Dermatol (2011) 0.96
Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant (2010) 0.95
Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain (2006) 0.95
Monitoring population health for Healthy People 2020: evaluation of the NIH PROMIS® Global Health, CDC Healthy Days, and satisfaction with life instruments. Qual Life Res (2012) 0.95
Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg (2014) 0.94
Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2006) 0.94
Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant (2012) 0.94
Use of US birth certificate data to estimate the risk of maternal cigarette smoking for oral clefting. Cleft Palate Craniofac J (2002) 0.93
Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases. J Immunol (2014) 0.92
Prenatal and perinatal factors associated with isolated oral clefting. Cleft Palate Craniofac J (2002) 0.91
Development of a focused microarray to assess human embryonic stem cell differentiation. Stem Cells Dev (2005) 0.91
The isomorphic response in morphealike chronic graft-vs-host disease. Arch Dermatol (2008) 0.90
Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. Biol Blood Marrow Transplant (2008) 0.89
Acupuncture treatment for persistent hiccups in patients with cancer. J Altern Complement Med (2010) 0.89
Quantitative salivary proteomic differences in oral chronic graft-versus-host disease. J Clin Immunol (2012) 0.89
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol (2004) 0.89
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. Oncology (2007) 0.88
Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-alpha (TGFA) gene and risk of oral cancer in Puerto Rico. Pharmacogenet Genomics (2005) 0.88
Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant (2009) 0.88
Quantitative measures of aggressive periodontitis show substantial heritability and consistency with traditional diagnoses. J Periodontol (2005) 0.88
Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer (2014) 0.87
Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis. Neuroimage Clin (2012) 0.87
Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One (2012) 0.87
Autologous hematopoietic stem cell transplantation for autoimmune disease--is it now ready for prime time? Biol Blood Marrow Transplant (2012) 0.87
Mechanisms of hearing loss in neurofibromatosis type 2. PLoS One (2012) 0.85
No association between selected candidate gene polymorphisms and severe chronic periodontitis. J Periodontol (2006) 0.84
Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor-alpha expression in adult oncology patients undergoing hematopoietic stem cell transplantation. Clin Ther (2007) 0.84
Do motor control genes contribute to interindividual variability in decreased movement in patients with pain? Mol Pain (2007) 0.83
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. J Clin Oncol (2012) 0.83
Cognitive impairment in patients with brain tumors: assessment and intervention in the clinic setting. Clin J Oncol Nurs (2006) 0.83